Lincoln Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹191 Cr +17.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
LP

Lincoln Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Lincoln Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹187Cr
+11.3% YoY
+12.7% QoQ
Net profit
₹12Cr
0% YoY
−58.6% QoQ
Margin
13%
−3 pp YoY
−1 pp QoQ

Based on Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹595
Market cap₹1.2K Cr
P/E12.6

The short version

The presentation reports the following for the quarter: - EBITDA: ₹26 crore, a 3% year-on-year increase - Operating Margin: 17.3%, a 150 basis points improvement year-on-year - Profit After Tax (PAT): ₹18 crore, an 8% year-on-year increase Regarding margin outlook:

From Lincoln Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.

Profitability & Margins

See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Lincoln Pharmaceuticals Ltd Q4 FY26 results — key figures

Lincoln Pharmaceuticals Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue187168+11.3%166+12.7%
Operating profit (EBITDA)2527-7.4%24+4.2%
Operating margin13%16%-3 pp14%-1 pp
Profit before tax1716+6.3%35-51.4%
Net profit (PAT)12120%29-58.6%
EPS (₹)5.815.78+0.5%14.28-59.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lincoln Pharmaceuticals Ltd Q4 FY26 results?

The presentation reports the following for the quarter: - EBITDA: ₹26 crore, a 3% year-on-year increase - Operating Margin: 17.3%, a 150 basis points improvement year-on-year - Profit After Tax (PAT): ₹18 crore, an 8% year-on-year increase Regarding margin outlook:

What is Lincoln Pharmaceuticals Ltd share price analysis?

Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.